FDA: Pfizer Concealed Serious Harm from Drugs

The world headquarters of Pfizer Inc. is seen in New York in this April 12, 2005 file photo. Pfizer has cut off all clinical trials and development for a cholesterol drug that was supposed to be the star of its pipeline because of an unexpected number of deaths and cardiovascular problems in patients who used it, the company said Saturday, Dec. 2, 2006. (AP Photo/Mark Lennihan)
AP Photo
Federal regulators have warned Pfizer for failing to promptly report complaints with its drugs that may have involved serious injury.

Pfizer repeatedly failed to submit product complaints to the Food and Drug Administration within the required 15 days, according to an FDA warning letter obtained by The Associated Press.

In some cases, Pfizer failed to report problems all together, including reports of serious side effects with the cholesterol drug Lipitor and the antiseizure drug Lyrica.

The New York-based company said in a statement it would work with the FDA to address the issues cited in the 12-page letter.

The FDA regularly issues warning letters to companies that do not follow regulations for manufacturing, marketing and testing.